Skip to main content

Table 5 Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study

From: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes

Sample number Lab number % Tumor cells Stage MYCN amp Ploidy Adrenal localisation Age Dead/alive Overall survival (months) Type
NB1 01T15 80 4S No Tri Yes < 1 year Alive 61.4 Favorable
NB2 98T33 95 1 No Tri Yes < 1 year Alive 76.9 Favorable
NB3 96T82 90 1 No Tri Yes < 1 year Alive 115.5 Favorable
NB4 99T129 90 1 No Tri Yes < 1 year Alive 71.7 Favorable
NB5 01T28 90 4 Yes Di Yes > 1 year Dead 5.6 Unfavorable
NB6 03T304 100 3a No Di Abdominal > 1 year Alive 12.0 Unfavorable
NB7 03T236 90 4 No ND Yes > 5 year Dead 19.4 Unfavorable
NB8 00T54 70 1 No Tri Yes < 1 year Alive 62.6 Favorable
NB9 00T35 > 95 4 Yes Di Yes < 1 year Dead 13.7 Unfavorable
NB10 99T125 80 3 No Di Yes > 5 year Alive 79.3 Unfavorable
NB11 92W145 70 4 No ND ND > 5 year Dead 19.5 Unfavorable
NB12 02T192 100 4 Yes Di Abdominal > 5 year Dead 16.2 Unfavorable
NB13 D031 > 95 4 No Di Abdominal > 1 year Dead 64.8 Unfavorable
NB14 E002 > 80 4 No ND Abdominal > 1 year Alive 65.7 Unfavorable
NB15 E037 > 80 4 No ND Abdominal > 1 year Alive 45.3 Unfavorable
NB16 E044 > 80 4 No ND Yes < 1 year Alive 37.0 Unfavorable
NB17 E121 > 80 4 Yes ND Abdominal > 1 year Dead 78.4 Unfavorable
NB18 04T121 60 3 Yes Di Yes > 1 year Dead 6 Unfavorable
  1. Based on stage, MYCN amplification, ploidy, and age at diagnosis, samples were subdivided into favorable or unfavorable type.
  2. aNeuroblastoma or ganglioneuroblastoma. ND, not determined or unknown.